About CMS

Current Location:About CMS > Major Events
2021

New drug application of Tildrakizumab accepted in China

Obtained the clinical trial notice of Methotrexate Injection, Pre-filled Syringe from China NMPA

Obtained the clinical trial notice of Methylthioninium Chloride Enteric-coated Sustained-release Tablets from China NMPA

Tildrakizumab obtained positive results of Phase Ⅲ clinical trial in China

New drug application of Diazepam Nasal Spray accepted in China

Entered into a strategic collaboration memorandum with EC Healthcare (2138.HK)

Acquired a medical aesthetic focused ultrasound technology platform company Shanghai Carnation Medical Technology Co., Ltd.

Equity investment in and establishment of a joint venture with Trinomab

Acquired a dermatology specialty company Luqa Ventures

Obtained the clinical trial notice of Desidustat Tablets (new molecular entity) from China NMPA

2020

Obtained clinical trial notices of Cyclosporine Eye Drops 0.09% and Tildrakizumab from China NMPA

Made equity investment in Gelesis; and acquired product rights of PLENITY®, a weight management product, in Mainland China and/or other countries or regions.

Acquired product rights of Desidustat Tablets (new molecular entity), Methotrexate Injection, Pre-filled Syringe, BCG for Intravesical Instillation, and Methylthioninium Chloride Enteric-coated Sustained-release Tablets in Mainland China and/or other countries or regions

2019

Obtained the clinical trial notice of Diazepam Nasal Spray from China NMPA

Acquired product rights of 7 innovative products including Cyclosporine Eye Drops 0.09%, Tildrakizumab and Paclitaxel Injection Concentrate for Suspension in Mainland China and/or other countries or regions

Acquired product rights of 11 generic drugs (including a complex generic drug) in Mainland China and/or other countries or regions

2018

Made equity investments in 4 overseas innovative R&D companies including Neurelis, Acticor Biotech, Blueberry Therapeutics and VAXIMM; and acquired assets or rights of 4 innovative products including Diazepam Nasal Spray, ACT017(anti-platelet humanized monoclonal antibody), BB2603(terbinafine-nano spray) and VXM01(oral T-cell immune agonist) in Mainland China and/or other countries or regions

Acquired product rights of 2 innovative products including novel lead small molecule compounds CF101 and CF102 in Greater China

Acquired assets of PoNS™(portable neuromodulation stimulator) in Mainland China and/or other countries or regions

2017

Made equity investment in Destiny Pharma;and acquired assets of XF-73 and other antibacterial product portfolio in Mainland China and/or other countries or regions

Continued to be the largest shareholder of Tibet Pharmaceutical with a total of 36.83% equity interest after completing the capital increase

2016

Obtained the exclusive right to commercialize Plendil in Mainland China

2015

Acquired Xili Pharmaceutical and obtained the exclusive sale and marketing rights of DanShenTong in Mainland China

Acquired assets of Hirudoid and Combizym in Mainland China and/or other countries or regions

2014

Became the largest shareholder of Tibet Pharmaceutical with a total of 26.61% equity interest

Acquired assets of Augentropfen Stulln Mono Eye-drops, MOVICOL® and Parlodel® in Mainland China and/or other countries or regions

2011

Acquired 100% equity interest of Tianjin Precede Medical Trade Development Co., Ltd. (officially renamed as Tianjin Kangzhe Pharmaceutical Technology Development Co., Ltd. on 24 October 2011)

2010

Listed on the Main Board of HKEX (Stock Code: 867)

Obtained the exclusive rights to promote and sell Bioflor in Mainland China

2008

Obtained the exclusive rights to promote and sell XinHuoSu, Cystistat and Salofalk in Mainland China

2006

Obtained the exclusive rights to promote and sell Augentropfen Stulln Mono Eye-drops and GanFuLe in Mainland China

2002

Obtained the exclusive rights to promote and sell Deanxit and Ursofalk in Mainland China

1998

Affiliated company obtained the exclusive rights to promote and sell Ursofalk in Mainland China

1997

Affiliated company obtained the exclusive rights to promote and sell Deanxit in Mainland China

1995

CMS was Established

2020

CMS was included in “CNI Nanshan 50 Index”

CMS has won the "The Best Hong Kong Stock-Connect Company" Award from Golden Hong Kong stocks

CMS was included in “Hang Seng Stock-Connect Biotech 50 Index”

2019

CMS has won the "Most Valuable Pharmaceuticals" Award from Golden Hong Kong stocks for three consecutive years

CMS was honored with three awards including “2019 Top 10 Listed Companies with the Highest Investment Value in China Pharmaceutical Industry”, “Top 100 Innovative Pharmaceutical Enterprises in China”, and “Benchmarking Enterprises in Pharmaceutical Industry at the 70th Anniversary of PRC Founding” at the China Healthcare Summit of Entrepreneurs, Scientists and Investors

Ms. Chen Yanling was awarded the “Best CFO of Hong Kong Listed Companies” in the Gelonghui’s First Best Listed Companies of Greater China Award

2018

CMS has won the "Most Valuable Pharmaceuticals" Award from Golden Hong Kong stocks for two consecutive years

CMS was successfully selected as “The Most Attractive Hong Kong Stock-Connect Companies for Institutional Investors”

CMS was awarded the title of "Honored Enterprise" in 2018 by the Journal of Institutional Investors; Ms. Chen Yanling was ranked "The Best Chief Financial Officer in Asia" in 2018 in the Journal of Institutional Investors for the seventh time in a row

CMS received the Golden Wing Prize "Most Changing Hong Kong Stock Exchange Company" by Stock Times

CMS received the award of "Shenzhen's Most Potential Employer in 2018"

2017

CMS once again won BIVA “Best Investment Value Award for Listed Companies”

CMS was awarded “The Most Valuable Pharmaceutical Company” by “Gold Hong Kong Stock” 

Shenzhen Kangzhe was awarded Top 100 Enterprises in Shenzhen in 2017

Shenzhen Kangzhe was awarded “2017 Top 100 Corporate Taxpayers“ in Nanshan District

CMS was awarded the title of “All-Asia Most Honored Company”; Mr. Lam Kong was awarded “Asia’s Best CEO” by “Institutional Investor” magazine in 2017; Ms. Chen Yanling was awarded “Asia’s Best CFO” by “Institutional Investor” Magazine in 2017; CMS’s investor relation team was awarded “Asia’s Best Investor Relations” in 2017

2016

Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” in 2016

CMS was awarded “The Most Valuable Investment of Listed Companies”

CMS was awarded “Top Ten Health Innovation Enterprises” by “M.D. Weekly”

Ms. Chen Yanling was awarded “Asia’s Best CFO”by“Institutional investor” magazine in 2016 for the fifth time consecutively

2015

Shenzhen Kangzhe was awarded “Top 100 Corporate Taxpayers in Nanshan District” in 2015

Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” in 2015

CMS was awarded “The Best Investor Relations” in the Greater China Awards Ceremony held by “Investors Relation (IR) Magazine”; Ms. Chen Yanling was awarded “Asia’s Best CFO” by“Institutional Investor” magazine for the fourth time consecutively

Tianjing Kangzhe was awarded “2014 Top 20 Science and Technology Small Giant Enterprise Certificate (Tianjin Development Zone)” for two consecutive years as well as the honorary title of “Top 100 Enterprises in Tianjing Development Zone”

CMS ranked on the list of Forbes on the “Best Enterprises Under a Billion” in 2015

CMS won the “Best Listed Company” award

2014

Mr. Lam Kong was awarded “Asia’s Best CEO” by “Institutional Investor” magazine in 2014; Ms. Chen Yanling was awarded “Asia’s Best CFO” by “Institutional Investor” magazine in 2014

CMS ranked in the list of Forbes on “Asia’s Best 200 Enterprises Under a Billion” in 2014

CMS won the “The Listed Company with the Best Information Disclosure”of the “2014 China Securities Golden Bauhinia Award” held by “Ta Kung Pao”

Shenzhen Kangzhe won “Top 100 Enterprises in Shenzhen” in 2014

2013

Ms. Chen Yanling won “Asia’s Best CFO” by “Institutional Investor” magazine in 2013

Shenzhen Kangzhe won “Top 100 Enterprises in Shenzhen” in 2013

2012

CMS ranked in the list of Forbes on “China's Best Up-And-Coming Businesses” in 2012

Ms. Chen Yanling won “Asia’s Best CFO” by “Institutional Investor” magazine in 2012

Tianjin Kangzhe was recognized as “Tianjin High-tech Enterprise”

Tianjin Kangzhe was awarded Certificate of “Tianjin A-grade Corporate Taxpayer”

2011

CMS ranked in the list of Forbes on “China's Best Up-And-Coming Businesses” in 2011

Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” in 2011

2010

CMS ranked in the list of Forbes on “China's Best Up-And-Coming Businesses” in 2010

Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” in 2010

Shenzhen Kangzhe was awarded “Top 100 Corporate Taxpayers in Nanshan District” in 2010

2009

Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” in 2009

Shenzhen Kangzhe was awarded “Top 100 Innovative Small and Medium Enterprises in Shenzhen” in 2009

2008

CMS ranked in the list of Forbes on “Asia’s Best 200 Enterprises Under a Billion” in 2008

Shenzhen Kangzhe was selected as "Leading Enterprises in Independent Innovative Industry"

Shenzhen Kangzhe was awarded "Top 100 Corporate Taxpayers in Nanshan District" in 2008

2004

Shenzhen Kangzhe was awarded “Top 100 Corporate Taxpayers” and “Top 100 Private Enterprise” of Futian district in 2004

Shenzhen Kangzhe was awarded “Top 50 Private Enterprise of Shenzhen”

2003

Shenzhen Kangzhe was awarded “Top 100 Corporate Taxpayers” and “Top 100 Private Enterprise” of Futian district in 2003

2002

Shenzhen Kangzhe was awarded “Top 100 Corporate Taxpayers” and “Top 100 Private Enterprise” of Futian district in 2002